A new formulation of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, currently dubbed GS 7340, achieves superior efficacy along with far higher concentrations inside the cells targeted by HIV for infection, compared with the current version of tenofovir (found in Viread, Truvada and Atripla). These data, which were presented Wednesday, March 7, at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, suggest that the drug may be an excellent candidate for fixed-dose combination tablets.
↧